Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder
Jaguar Health's subsidiary Napo Pharmaceuticals reports that liquid oral crofelemer reduced daily parenteral support needs by roughly 15% in an infant with congenital sodium diarrhea due to a GUCY2C mutation, the third rare intestinal-failure indication being evaluated under expanded access. In longer-dosed pediatric patients, weekly PS requirements normalized to body weight fell up to 48% in an MVID patient and up to 40% in two SBS-IF patients after more than 12 months of high-dose therapy, with no significant clinical or laboratory abnormalities.
Key figures
- Drug Name
- crofelemer (powder for oral solution)
- Nda filing target
- mid-2027 for MVID
- Pivotal trial status
- enrollment completed
- Ps reduction csd patient
- ~15% daily parenteral support reduction within first several weeks
- Ps reduction mvid patient
- up to 48% weekly PS normalized to body weight after >12 months
- Ps reduction sbs if patients
- up to 40% weekly PS normalized to body weight after >12 months
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.